重组人干细胞因子治疗骨髓增生异常综合征的临床可能性

Potential of Recombinant Human Stem Cell Factor in the Treatment of Myelodysplastic Syndrome

为明确骨髓增生异常综合征(MDS)患者造血祖细胞对重组人干细胞因于(rhSCF)的反应性,使用无血清培养体系体外培养,比较MDS与正常人红、粒系克隆性生长能力.结果表明,两例难治性贫血(RA)在rhSCF+重组人白介素3(rhlL-3)+重组人促红素(rhEPO)三因于联合刺激作用下,早期红系祖细胞(BFU-E)克隆生长接近正常水平.促粒系造血方面,rhSCF+rhIL-3或重组人粒/巨噬细胞集落刺激因子(rhGM-CSF)联合作用下,粒/巨噬祖细胞(CFU-GM)克隆生长虽未达正常水平,却较单一rhIL-3或rhGM-CSF高7～29倍或5.6～12倍.结论:至少部分MDS患者的红系祖细胞数量并未减少.rhSCF与其它造血生长因子联合治疗MDS有重要临床意义.

The clonal growth of erythrocytic and granulocytic lineage in myelodysplastic syndrome(MDS) and the normal was observed to clarify the respone of MDS hematopoietic progenitors to recombinant human stem cell factor(rhSCF). The results show that BFU-E of 2 cases of refractory anemia(RA), when cultured with rhSCF+rhIL-3 + rhEPO, were comparable to those of the normal(P>0.05), and that CFU-GM of all MDS studied, when with rhSCF+rhIL-3 or rhGM-CSF, were inferior to those of the nomal(P<0.05). In conclusion rhSCF possesses the potential in the treatment of anemia and granulepenia caused by MDS.